Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 5/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7507622 | 0.84 | SRC (1.00) | SRCEGFRABL1PIK3CDPIK3CA | |
| SCHEMBL14982762 | 0.83 | SRC (0.72) | SRCEGFRABL1RET | |
| SCHEMBL7509503 | 0.81 | SRC (1.00) | SRCEGFRABL1RETPIK3CD | |
| SCHEMBL7512313 | 0.81 | SRC (1.00) | SRCABL1RET | |
| SCHEMBL1318686 | 0.80 | SRC (0.66) | SRCEGFRABL1RETBTK | |
| SCHEMBL12120715 | 0.79 | SRC (0.65) | SRCEGFRRETERBB2ERBB3 | |
| SCHEMBL863906 | 0.79 | SRC (0.64) | SRCEGFRABL1RETPIK3CD | |
| SCHEMBL864574 | 0.79 | SRC (0.64) | SRCEGFRABL1RETPIK3CD | |
| SCHEMBL863586 | 0.79 | SRC (0.64) | SRCEGFRABL1BTKPIK3CD | |
| SCHEMBL12120474 | 0.77 | SRC (0.62) | SRCEGFRRETBTKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2011153553-A2 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | SRC, ABL1, LCK | SRC 1/4885EGFR 132/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.